Abstract
The phenylethylamine, 3,4-methylenedioxymethamphetamine (MDMA, ‘ecstasy’), is the prototypical example of an entactogen. Its original placement in highly restrictive drug usage categories in the US and UK, led to an inevitable restriction on MDMA neuroscience research and treatment. The dominant pharmacological effects of MDMA are its properties of release and inhibition of reuptake of amine neurotransmitter transporters for dopamine, norepinephrine, and serotonin. MDMA is an agonist of a wide range of receptors; its mood-altering effects are mediated via 5-HT2A receptors; this receptor may also mediate its effects on body temperature, analgesia, and anxiolytic properties. The mechanisms underlying MDMA’s entactogenic properties of sociability and interpersonal closeness are not known but release and involvement of oxytocin, a peptide thought by some to be involved in social bonding, has been suggested. Adverse effects of MDMA are mostly transient; acute multiorgan adverse effects occurring during raves or crowded dance gatherings include dehydration, hyperthermia, seizures, rhabdomyolysis, disseminated intravascular coagulation, and acute renal failure. Deaths following MDMA taken by itself are rare compared to fatalities following coadministration with other drugs. A recent FDA-approved phase 3 clinical trial of MDMA for post-traumatic stress disorder (PTSD) led to the conclusion that MDMA-assisted therapy represents a potential breakthrough treatment meriting expedited clinical evaluation. Despite the ongoing deliberations by the FDA and EMA for approval of MDMA treatment of PTSD, the Australian Therapeutic Goods Administration (TGA) recently announced that after an evaluation of the therapeutic value, benefits, and risks of MDMA, it will permit its prescribing for the treatment of PTSD. Further examples of regulatory relaxation toward MDMA-assisted psychotherapy are underway. These include the FDA’s recently approved clinical trial to assess MDMA’s efficacy in the treatment of “asociality” in patients with schizophrenia and an open trial of MDMA treatment for alcohol-use disorder which showed decreased alcohol consumption. There are also ongoing studies on the little understood startle response, anxiety associated with life-threatening illness, and social anxiety in autistic adults.
This is a preview of subscription content, log in via an institution to check access.
Reproduced from Cohen, IV et al., 2021. Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database. Sci Rep 11, 5997. https://doi.org/10.1038/s41598-021-85389-x, an Open Access article licensed under a Creative Commons Attribution 4.0 International License
Reproduced from Cohen, IV et al., 2021. Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database. Sci Rep 11, 5997. https://doi.org/10.1038/s41598-021-85389-x, an Open Access article licensed under a Creative Commons Attribution 4.0 International License
Reproduced from Cohen, IV et al., 2021. Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database. Sci Rep 11, 5997. https://doi.org/10.1038/s41598-021-85389-x, an Open Access article licensed under a Creative Commons Attribution 4.0 International License
Similar content being viewed by others
Data availability
Data are available from the author on request.
References
ACMD (Advisory Council on the Misuse of Drugs). MDMA (‘ecstasy’): A review of its harms and classification under the Misuse of Drugs Act 1971 (Nutt DJ, 2008) https://assets.publishing.service.gov.uk/media/5a7ad072e5274a34770e74e6/mdma-report.pdf (Accessed Oct 20, 2023)
Ajaelo I, Koenig K, Snoey E (1998) Severe hyponatremia and inappropriate antidiuretic hormone secretion following ecstasy use. Acad Emerg Med 5(8):839–840. https://doi.org/10.1111/j.1553-2712.1998.tb02512.x
Assi S, Gulyamova N, Ibrahim K, Kneller P, Osselton D (2017) Profile, effects, and toxicity of novel psychoactive substances: a systematic review of quantitative studies. Hum Psychopharmacol. https://doi.org/10.1002/hup.2607
Baldo BA (2018) Opioid analgesic drugs and serotonin toxicity (syndrome): mechanisms, animal models, and links to clinical effects. Arch Toxicol 92:2457–2473. https://doi.org/10.1007/s00204-018-2244-6
Baldo BA (2023) Allergic and other adverse reactions to drugs used in anesthesia and surgery. Anaesthesiol Perioper Sci 1:16. https://doi.org/10.1007/s44254-023-00018-2
Baldo BA, Pham NH (2021) Drug allergy: clinical aspects, diagnosis, mechanisms structure-activity relationships, 2nd edn. Springer Nature, Cham, Switzerland. https://doi.org/10.1007/978-3-030-51740-3
Ball KT, Rebec GV (2005) Role of 5-HT2A and 5-HT2C/B receptors in the acute effects of 3,4-methylenedioxymethamphetamine (MDMA) on striatal single-unit activity and locomotion in freely moving rats. Psychopharmacology 181(4):676–687. https://doi.org/10.1007/s00213-005-0038-z
Ball KT, Budreau D, Rebec GV (2003) Acute effects of 3,4-methylenedioxymethamphetamine on striatal single-unit activity and behavior in freely moving rats: differential involvement of dopamine D(1) and D(2) receptors. Brain Res 994(2):203–215. https://doi.org/10.1016/j.brainres.2003.09.037
Battaglia G, Brooks BP, Kulsakdinun C, De Souza EB (1998) Pharmacologic profile of MDMA (3,4-methylenedioxymethamphetamine) at various brain recognition sites. Eur J Pharmacol 149(1–2):159–163. https://doi.org/10.1016/0014-2999(88)90056-8
Baumeister D, Tojo LM, Tracy DK (2015) Legal highs: staying on top of the flood of novel psychoactive substances. Ther Adv Psychopharmacol 5(2):97–132. https://doi.org/10.1177/2045125314559539
Bogen IL, Haug KH, Myhre O, Fonnum F (2003) Short- and long-term effects of MDMA (“ecstasy”) on synaptosomal and vesicular uptake of neurotransmitters in vitro and ex vivo. Neurochem Int 43(4–5):393–400. https://doi.org/10.1016/s0197-0186(03)00027-5
Broadbear JH, Kabel D, Tracy L, Mak P (2014) Oxytocinergic regulation of endogenous as well as drug-induced mood. Pharmacol Biochem Behav 119:61–71. https://doi.org/10.1016/j.pbb.2013.07.002
Brown C, Osterloh J (1987) Multiple severe complications from recreational ingestion of MDMA (Ecstasy’). JAMA 258:780–781
Buckley NA, Dawson AH, Isbister GK (2014) Serotonin syndrome. BMJ 19(348):g1626. https://doi.org/10.1136/bmj.g1626
Cami J, Farré M, Mas M, Roset PN, Poudevida S, Mas A, San L, de la Torre R (2000) Human pharmacology of 3,4-methylenedioxymethamphetamine (“ecstasy”): psychomotor performance and subjective effects. J Clin Psychopharmacol 20(4):455–466. https://doi.org/10.1097/00004714-200008000-00010
Campkin NTA, Davies UM (1992) Another death from ecstasy. J R Soc Med 85:61
CFSRE NPS Discovery. Available at https://www.cfsre.org/images/trendreports/yir-2021/YearInReview-2021.pdf. (Accessed Aug 15, 2023)
Chabrol H, Oehen P (2013) MDMA assisted psychotherapy found to have a large effect for chronic post-traumatic stress disorder. J Psychopharmacol 27:865–866. https://doi.org/10.1177/0269881113495119
Chadwick IS, Linsley A, Freemont AJ et al (1991) Ecstasy, 3–4 methylenedioxymethamphetamine (MDMA), a fatality associated with coagulopathy and hyperthermia. J R Soc Med 84:371. https://doi.org/10.1177/014107689108400622
Cohen IV, Makunts T, Abagyan RT, K, (2021) Concomitant drugs associated with increased mortality for MDMA users reported in a drug safety surveillance database. Sci Rep 11:5997. https://doi.org/10.1038/s41598-021-85389-x
Consumption ecstasy in Australia (2023) Available at https://ndarc.med.unsw.edu.au/news/major-changes-australian-drug-use-during-2021-says-annual-drug-trends-reports. (Accessed Novemb 30 2023)
Consumption ecstasy in Europe (2023) Available at https://www.emcdda.europa.eu/publications/european-drug-report/2023/mdma_en (Accessed Novemb 30 2023)
Consumption ecstasy in US (2023) Available at https://nida.nih.gov/publications/research-reports/mdma-ecstasy-abuse/what-is-the-scope-of-mdma-use-in-the-united-states (Accessed Novemb 30 2023)
Costa G, Golembiowska K (2022) Neurotoxicity of MDMA: main effects and mechanisms. Exp Neurol 347:113894. https://doi.org/10.1016/j.expneurol.2021.113894
Cottler LB, Leung KS, Abdallah AB (2009) Test-re-test reliability of DSM-IV adopted criteria for 3,4-methylenedioxymethamphetamine (MDMA) abuse and dependence: a cross-national study. Addict Abingdon Engl 104(10):1679–1690. https://doi.org/10.1111/j.1360-0443.2009.02649.x
Council decision European Union (2005) Council decision 2005/387/JHA of 20 May 2005 on the information exchange, risk assessment and control of new psychoactive substances. Off J Eur Union L 127/32
Danforth AL, Grob CS, Struble C et al (2018) Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. Psychopharmacology 235:3137–3148. https://doi.org/10.1007/s00213-018-5010-9
Davis AK, Rosenberg H (2017) Specific harm reduction strategies employed by 3,4-methylenedioxymethamphetmine/ ecstasy users in the United States and the United Kingdom. Drug Sci Policy Law. https://doi.org/10.1177/2050324517711069
Davison D, Parrott AC (1997) Ecstasy (MDMA) in recreational users: self-reported psychological and physiological effects. Hum Psychopharmacol 12:221–226. https://doi.org/10.1002/(SICI)1099-1077(199705/06)12:3%3c221::AID-HUP854%3e3.0.CO;2-C
de la Torre R, Farré M, Roset PN, Pizarro N, Abanades S, Segura M, Segura J, Camí J (2004) Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther Drug Monit 26(2):137–144. https://doi.org/10.1097/00007691-200404000-00009
de la Torre R, Yubero-Lahoz S, Pardo-Lozano R, Farré M (2012) MDMA, methamphetamine, and CYP2D6 pharmacogenetics: what is clinically relevant? Front Genet 12(3):235. https://doi.org/10.3389/fgene.2012.00235
Degenhardt L, Bruno R, Topp L (2010) Is ecstasy a drug of dependence? Drug Alcohol Depend 107(1):1–10. https://doi.org/10.1016/j.drugalcdep.2009.09.009
Dignam G, Bigham C (2017) Novel psychoactive substances: a practical approach to dealing with toxicity from legal highs. BJA Educ 17:172–177. https://doi.org/10.1093/bjaed/mkw068
Dowling GP, McDonough ET 3rd, Bost RO (1987) A report of five deaths associated with the use of MDEA and MDMA. JAMA 257(12):1615–1617. https://doi.org/10.1001/jama.257.12.1615
Downing J (1986) The psychological and physiological effects of MDMA on normal volunteers. J Psychoactive Drugs 18(4):335–340. https://doi.org/10.1080/02791072.1986.10472366
Eiden C, Mathieu O, Cathala P, Debruyne D, Baccino E, Petit P, Peyriere H (2013) Toxicity and death following recreational use of 2-pyrrolidino valerophenone. Clin Toxicol (phila) 51(9):899–903. https://doi.org/10.3109/15563650.2013.847187
EMCDDA (2023) New psychoactive substances: health and social responses. Available from https://www.emcdda.europa.eu/publications/mini-guides/new-psychoactive-substances-health-and-social-responses_en (Accessed 30 Oct 2023)
Emerick TD, Martin TJ, Ririe DG (2023) Perioperative considerations for patients exposed to psychostimulants. Anesth Analg 137(3):474–487. https://doi.org/10.1213/ANE.0000000000006303
Fallon JK, Shah D, Kicman AT, Hutt AJ, Henry JA, Cowan DA, Forsling M (2002) Action of MDMA (ecstasy) and its metabolites on arginine vasopressin release. Ann N Y Acad Sci 965:399–409. https://doi.org/10.1111/j.1749-6632.2002.tb04181.x
Feduccia AA, Jerome L, Yazar-Klosinski B, Emerson A, Mithoefer MC, Doblin R (2019) Breakthrough for trauma treatment: Safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline. Front Psychiatry 10:650. https://doi.org/10.3389/fpsyt.2019.00650
Fitzgerald JL, Reid JJ (1990) Effects of methylenedioxymethamphetamine on the release of monoamines from rat brain slices. Eur J Pharmacol 191(2):217–220. https://doi.org/10.1016/0014-2999(90)94150-v
Forsling M, Fallon JK, Kicman AT, Hutt AJ, Cowan DA, Henry JA (2001) Arginine vasopressin release in response to the administration of 3,4-methylenedioxymethamphetamine (“ecstasy”): is metabolism a contributory factor? J Pharm Pharmacol 53(10):1357–1363. https://doi.org/10.1211/0022357011777855
Forsling ML, Fallon JK, Shah D, Tilbrook GS, Cowan DA, Kicman AT, Hutt AJ (2002) The effect of 3,4-methylenedioxymethamphetamine (MDMA, ’ecstasy’) and its metabolites on neurohypophysial hormone release from the isolated rat hypothalamus. Br J Pharmacol 135(3):649–656. https://doi.org/10.1038/sj.bjp.0704502
Freedman RR, Johanson CE, Tancer ME (2005) Thermoregulatory effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans. Psychopharmacology 183(2):248–256. https://doi.org/10.1007/s00213-005-0149-6
German CL, Fleckenstein AE, Hanson GR (2014) Bath salts and synthetic cathinones: an emerging designer drug phenomenon. Life Sci 97(1):2–8. https://doi.org/10.1016/j.lfs.2013.07.023
Gledhill JA, Moore DF, Bell D, Henry JA (1993) Subarachnoid hemorrhage associated with MDMA abuse. J Neurol Neurosurg Psych 56(9):1036–1037. https://doi.org/10.1136/jnnp.56.9.1036
Golder S, Loke YK, Wright K, Norman G (2016) Reporting of adverse events in published and unpublished studies of health care interventions: a systematic review. PLoS Med 13(9):e1002127. https://doi.org/10.1371/journal.pmed.1002127
Green AR, Mechan AO, Elliott JM, O’Shea E, Colado MI (2003) The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”). Pharmacol Rev 55(3):463–508. https://doi.org/10.1124/pr.55.3.3
Greer G, Tolbert R (1986) Subjective reports of the effects of MDMA in a clinical setting. J Psychoactive Drugs 18(4):319–327. https://doi.org/10.1080/02791072.1986.10472364
Greer GR, Tolbert R (1990) The therapeutic use of MDMA. In: Peroutka SJ (ed) Ecstasy The Clinical Pharmacological and Neurotoxicological Effects of the Drug MDMA Topics in the Neurosciences. Springer, Boston, pp 21–35
Gu XF, Azmitia EC (1993) Integrative transporter-mediated release from cytoplasmic and vesicular 5-hydroxytryptamine stores in cultured neurons. Eur J Pharmacol 235(1):51–57. https://doi.org/10.1016/0014-2999(93)90819-4
Gulliver D, Werry E, Reekie TA, Katte TA, Jorgensen W, Kassiou M (2019) Targeting the oxytocin system: New pharmacotherapeutic approaches. Trends Pharmacol Sci 40(1):22–37. https://doi.org/10.1016/j.tips.2018.11.001
Halpern JH, Pope HG, Sherwood AR, Barry S, Hudson JI, Todd D et al (2004) Residual neuropsychological effects of illicit 3,4- methelenedioxymethamphetamine (MDMA) in individuals with minimal exposure to other drugs. Drug Alcohol Depend 75:135–147. https://doi.org/10.1016/j.drugalcdep.2004.02.008
Han DD, Gu HH (2006) Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol 3(6):6. https://doi.org/10.1186/1471-2210-6-6
Harries DP, De Silva R (1992) “Ecstasy” and intracerebral haemorrhage. Scott Med J 37(5):150–152. https://doi.org/10.1177/003693309203700508
Henry JA, Jeffreys KJ, Dawling S (1992) Toxicity and deaths from 3,4-methylenedioxy- methamphetamine ('ecstasy’). Lancet 340:384–387. https://doi.org/10.1016/0140-6736(92)91469-o
Heyerdahl F, Hovda KE, Giraudon I, Yates C, Dines AM, Sedefov R, Wood DM, Dargan PI (2014) Current European data collection on emergency department presentations with acute recreational drug toxicity: gaps and national variations. Clin Toxicol (phila) 52(10):1005–1012. https://doi.org/10.3109/15563650.2014.976792
Hill SL, Thomas SH (2011) Clinical toxicology of newer recreational drugs. Clin Toxicol (phila) 49(8):705–719. https://doi.org/10.3109/15563650.2011.615318. (Erratum in: Clin Toxicol (Phila) 49(9):880)
Holden R, Jackson MA (1996) Near-fatal hyponatraemic coma due to vasopressin over-secretion after “ecstasy” (3,4-MDMA). Lancet 347(9007):1052. https://doi.org/10.1016/s0140-6736(96)90196-8
Holland J (Ed.) (2001) Ecstasy: The complete guide: A comprehensive look at the risks and benefits of MDMA. Park Street Press
Hughes JC, McCabe M, Evans RJ (1993) Intracranial haemorrhage associated with ingestion of “ecstasy.” Arch Emerg Med 10:372–374. https://doi.org/10.1136/emj.10.4.372
Isbister GK, Buckley NA, Whyte IM (2007) Serotonin toxicity: a practical approach to diagnosis and treatment. Med J Aust 187:361–365. https://doi.org/10.5694/j.1326-5377.2007.tb01282.x
Jerome L, Feduccia AA, Wang JB, Hamilton S, Yazar-Klosinski B, Emerson A, Mithoefer MC, Doblin R (2020) Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials. Psychopharmacology 237(8):2485–2497. https://doi.org/10.1007/s00213-020-05548-2
Johnston CB, Mangini M, Grob C, Anderson B (2023) The safety and efficacy of psychedelic-assisted therapies for older adults: Knowns and unknowns. Am J Geriatr Psychiatry 31(1):44–53. https://doi.org/10.1016/j.jagp.2022.08.007
Jørgensen H, Riis M, Knigge U, Kjaer A, Warberg J (2003) Serotonin receptors involved in vasopressin and oxytocin secretion. J Neuroendocrinol 15(3):242–249. https://doi.org/10.1046/j.1365-2826.2003.00978.x
Kirkpatrick MG, Lee R, Wardle MC, Jacob S, de Wit H (2014) Effects of MDMA and intranasal oxytocin on social and emotional processing. Neuropsychopharmacology 2039(7):1654–1663. https://doi.org/10.1038/npp.2014.12
Kolbrich EA, Goodwin RS, Gorelick DA, Hayes RJ, Stein EA, Huestis MA (2008) Physiological and subjective responses to controlled oral 3,4-methylenedioxymethamphetamine administration. J Clin Psychopharmacol 28(4):432–440. https://doi.org/10.1097/JCP.0b013e31817ef470
Kuypers KP, de la Torre R, Farre M, Yubero-Lahoz S, Dziobek I, Van den Bos W, Ramaekers JG (2014) No evidence that MDMA-induced enhancement of emotional empathy is related to peripheral oxytocin levels or 5-HT1a receptor activation. PLoS ONE 9(6):e100719. https://doi.org/10.1371/journal.pone.0100719
Kuypers KPC, de la Torre R, Farre M, Pizarro N, Xicota L, Ramaekers JG (2018) MDMA-induced indifference to negative sounds is mediated by the 5-HT2A receptor. Psychopharmacology 235(2):481–490. https://doi.org/10.1007/s00213-017-4699-1.Erratum.In:Psychopharmacology(Berl)2017Aug1;PMID:28735368;PMCID:PMC5813067
Leonardi ET, Azmitia EC (1994) MDMA (ecstasy) inhibition of MAO type A and type B: comparisons with fenfluramine and fluoxetine (Prozac). Neuropsychopharmacology 10(4):231–238. https://doi.org/10.1038/npp.1994.26
Li C, Wang W, Summer SN, Westfall TD, Brooks DP, Falk S, Schrier RW (2008) Molecular mechanisms of antidiuretic effect of oxytocin. J Am Soc Nephrol 19(2):225–232. https://doi.org/10.1681/ASN.2007010029
Liechti M (2015) Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling. Swiss Med Wkly 145:w14043. https://doi.org/10.4414/smw.2015.14043
Liechti ME, Saur MR, Gamma A, Hell D, Vollenweider FX (2000) Psychological and physiological effects of MDMA (“Ecstasy”) after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans. Neuropsychopharmacology 23(4):396–404. https://doi.org/10.1016/S0893-133X(00)00126-3
Liester MB, Grob CS, Bravo GL, Walsh RN (1992) Phenomenology and sequelae of 3,4-methylenedioxymethamphetamine use. J Nerv Ment Dis 180(6):345–352. https://doi.org/10.1097/00005053-199206000-00001
Ludewig S, Ludewig K, Hasler F, Vollenweider FX (2003) No lasting effects of moderate doses of MDMA (Ecstasy) on memory performance and mood states in healthy humans. Biol Psychiatry 53(8):205S
Lykos Therapeutics announces FDA acceptance and Priority Review of New Drug application for MDMA-assisted therapy for PTSD. Available from https://news.lykospbc.com/2024-02-09-Lykos-Therapeutics-Announces-FDA-Acceptance-and-Priority-Review-of-New-Drug-Application-for-MDMA-Assisted-Therapy-for-PTSD. Accessed 5 May 2024
Makunts T, Jerome L, Abagyan R, de Boer A (2022) Reported cases of serotonin syndrome in MDMA users in FAERS database. Front Psychiatry 24(12):824288. https://doi.org/10.3389/fpsyt.2021.824288
Manchanda S, Connolly MJ (1993) Cerebral infarction in association with Ecstasy abuse. Postgrad Med J 69(817):874–875. https://doi.org/10.1136/pgmj.69.817.874
Maples-Keller JL, Norrholm SD, Burton M et al (2022) A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults. J Psychopharmacol 36(3):368–377. https://doi.org/10.1177/02698811211069124
MAPS Public Benefit Corporation Investigator’s brochure (2023) Available at https://maps.org/wp-content/uploads/2023/04/MDMA-IB-15th-Edition_FINAL_13MAR2023_MRC.pdf (Accessed Sept 20, 2023)
Mas M, Farre M, de la Torre R, Roset PN, Ortuño J, Segura J et al (1999) Cardiovascular and neuroendocrine effects and pharmacokinetics of 3, 4- methylenedioxymethamphetamine in humans. J Pharmacol Exp Ther 290:136–145
McCann UD, Slate SO, Ricaurte GA (1996) Adverse reactions with 3,4-methylenedioxymethamphetamine (MDMA; ’ecstasy’). Drug Saf 15(2):107–115. https://doi.org/10.2165/00002018-199615020-00003
Mitchell JM, Bogenschutz M, Lilienstein A, Harrison C, Kleiman S, Parker-Guilbert K et al (2021) MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med 27(6):1025–1033. https://doi.org/10.1038/s41591-021-01336-3
Mitchell JM, Ot’alora GM, van der Kolk B, Shannon S, Bogenschutz M, Gelfand Y et al (2023) MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. Nat Med 29(10):2473–2480. https://doi.org/10.1038/s41591-023-02565-4
Mithoefer MC, Wagner TM, Mithoefer AT, Jerome L, Doblin R (2011) The safety and efficacy of ±3,4-methylenedioxymethamphetamine-assisted psychotherapy in subjects with chronic, treatment-resistant posttraumatic stress disorder: the first randomized controlled pilot study. J Psychopharmacol 25:439–452. https://doi.org/10.1177/0269881110378371
Mithoefer MC, Wagner MT, Mithoefer AT, Jerome L, Martin SF, Yazar-Klosinski B et al (2013) Durability of improvement in post-traumatic stress disorder symptoms and absence of harmful effects or drug dependence after 3,4-methylenedioxymethamphetamine-assisted psychotherapy: a prospective long-term follow- up study. J Psychopharmacol 27:28–39. https://doi.org/10.1177/0269881112456611
Mithoefer MC, Mithoefer AT, Feduccia AA, Jerome L, Wagner M, Wymer J et al (2018) 3,4-Methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. Lancet Psychiatry 5:486–497. https://doi.org/10.1016/S2215-0366(18)30135-4
Mithoefer MC, Jerome L, Mithoefer A, Wagner M, Walsh Z et al (2019) MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials. Psychopharmacology 236:2735–2745. https://doi.org/10.1007/s00213-019-05249-5
Mwambingu FT (1985) Water intoxication and oxytocin. Br Med J (clin Res Ed). https://doi.org/10.1136/bmj.290.6462.113
Nardou R, Lewis EM, Rothhaas R, Xu R, Yang A, Boyden E, Dölen G (2019) Oxytocin-dependent reopening of a social reward learning critical period with MDMA. Nature 569(7754):116–120. https://doi.org/10.1038/s41586-019-1075-9
Nichols DE (1986) Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. identification of a new therapeutic class: entactogens. J Psychoact Drugs 18(4):305–313. https://doi.org/10.1080/02791072.1986.10472362
Nichols DE (2016) Psychedelics. Pharmacol Rev 68(2):264–355. https://doi.org/10.1124/pr.115.011478.Erratum.In:PharmacolRev68(2):356
Nichols DE (2022) Entactogens: how the name for a novel class of psychoactive agents originated. Front Psychiatry 13:863088. https://doi.org/10.3389/fpsyt.2022.863088
Nichols DE, Johnson MW, Nichols CD (2017) Psychedelics as medicines: An emerging new paradigm. Clin Pharmacol Ther 101(2):209–219. https://doi.org/10.1002/cpt.557
NIDA (2022) What is MDMA?. National Institute on Drug Abuse website. https://nida.nih.gov/publications/research-reports/mdma-ecstasy-abuse/what-mdma. Dec 19, 2022. Accessed Febr 19, 2024
Nutt DJ, King LA, Nichols DE (2013) Effects of Schedule I drug laws on neuroscience research and treatment innovation. Nat Rev Neurosci 14:577–585. https://doi.org/10.1038/nrn3530
Oehen P, Traber R, Widmer V, Schnyder U (2013) A randomized, controlled pilot study of MDMA (±3,4-methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic post-traumatic stress disorder (PTSD). J Psychopharmacol 27:40–52. https://doi.org/10.1177/0269881112464827
Oeri HE (2021) Beyond ecstasy: Alternative entactogens to 3,4-methylenedioxymethamphetamine with potential applications in psychotherapy. J Psychopharmacol 35(5):512–536. https://doi.org/10.1177/0269881120920420
Ota’lora G, Grigsby J, Poulter B, Van Derveer JW, III, Giron SG, Jerome L, et al (2018) MDMA-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: a randomized controlled trial. J Psychopharmacol 32:1295–1307. https://doi.org/10.1177/0269881118806297
Parr MJ, Low HM, Botterill P (1997) Hyponatraemia and death after “ecstasy” ingestion. Med J Aust 166(3):136–137. https://doi.org/10.5694/j.1326-5377.1997.tb140044.x
Partilla JS, Dempsey AG, Nagpal AS, Blough BE, Baumann MH, Rothman RB (2006) Interaction of amphetamines and related compounds at the vesicular monoamine transporter. J Pharmacol Exp Ther 319(1):237–246. https://doi.org/10.1124/jpet.106.103622
Pentney AR (2001) An exploration of the history and controversies surrounding MDMA and MDA. J Psychoactive Drugs 33(3):213–221. https://doi.org/10.1080/02791072.2001.10400568
Peroutka SJ, Newman H, Harris H (1988) Subjective effects of 3,4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1(4):273–277
Peryer G, Golder S, Junqueira D, et al (2021) Chapter 19: Adverse effects. In: Higgins JPT, Thomas J, Chandler J, et al. (eds) Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (Updated Febr 2021). Cochrane. Available at: http://www.training.cochrane.org/handbook (accessed 21 October 2023).
Pilecki B, Luoma JB, Bathje GJ et al (2021) Ethical and legal issues in psychedelic harm reduction and integration therapy. Harm Reduct J 18:40. https://doi.org/10.1186/s12954-021-00489-1
Pilgrim JL, Gerostamoulos D, Woodford N, Drummer OH (2012) Serotonin toxicity involving MDMA (ecstasy) and moclobemide. Forensic Sci Int 215(1–3):184–188. https://doi.org/10.1016/j.forsciint.2011.04.008
Preller KH, Vollenweider FX (2019) Modulation of social cognition via hallucinogens and “Entactogens.” Front Psychiatry 10:881. https://doi.org/10.3389/fpsyt.2019.00881
Prosser JM, Nelson LS (2011) The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol. https://doi.org/10.1007/s13181-011-0193-z
Renaud LP, Bourque CW (1991) Neurophysiology and neuropharmacology of hypothalamic magnocellular neurons secreting vasopressin and oxytocin. Prog Neurobiol 36(2):131–169. https://doi.org/10.1016/0301-0082(91)90020-2
Report to the Therapeutic Goods Administration (2023) Available at: https://www.tga.gov.au/sites/default/files/mmda-and-psilocybin-independent-expert-panel-review-final-report.pdf (Accessed Oct 3 2023)
Rickli A, Kopf S, Hoener MC, Liechti ME (2015) Pharmacological profile of novel psychoactive benzofurans. Br J Pharmacol 172(13):3412–3425. https://doi.org/10.1111/bph.13128
Rollason V, Lloret-Linares C, Lorenzini KI, Daali Y, Gex-Fabry M, Piguet V et al (2020) Evaluation of phenotypic and genotypic variations of drug metabolising enzymes and transporters in chronic pain patients facing adverse drug reactions or non-response to analgesics: a retrospective study. J Pers Med 10(4):198. https://doi.org/10.3390/jpm10040198
Rothman RB, Baumann MH (2003) Monoamine transporters and psychostimulant drugs. Eur J Pharmacol 479(1–3):23–40. https://doi.org/10.1016/j.ejphar.2003.08.054
Rothwell PM, Grant R (1993) Cerebral venous sinus thrombosis induced by “ecstasy.” J Neurol Neurosurg Psychiatry 56(9):1035–1039. https://doi.org/10.1136/jnnp.56.9.1035
Roxburgh A, Lappin J (2020) MDMA-related deaths in Australia 2000 to 2018. Int J Drug Policy 76:102630. https://doi.org/10.1016/j.drugpo.2019.102630
Rudin D, Liechti ME, Luethi D (2021) Molecular and clinical aspects of potential neurotoxicity induced by new psychoactive stimulants and psychedelics. Exp Neurol 343:113778. https://doi.org/10.1016/j.expneurol.2021.113778
Rudnick G, Wall SC (1992) The molecular mechanism of “ecstasy” [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc Natl Acad Sci USA 89(5):1817–1821. https://doi.org/10.1073/pnas.89.5.1817
Schifano F, Oyefeso A, Webb L, Pollard M, Corkery J, Ghodse AH (2003) Review of deaths related to taking ecstasy, England and Wales, 1997–2000. BMJ 326:80–81. https://doi.org/10.1136/bmj.326.7380.80
Schifano F, Corkery J, Naidoo V, Oyefeso A, Ghodse H (2010) Overview of amphetamine-type stimulant mortality data—UK, 1997–2007. Neuropsychobiology 61:122–130. https://doi.org/10.1159/000279302
Schifano F, Napoletano F, Chiappini S, Guirguis A, Corkery J, Bonaccorso S et al (2021) New/emerging psychoactive substances and associated psychopathological consequences. Psychol Med 51(1):30–42. https://doi.org/10.1017/S0033291719001727
Schilt T, Koeter MW, Smal JP, Gouwetor MN, van den Brink W, Schmand B (2010) Long-term neuropsychological effects of ecstasy in middle-aged ecstasy/polydrug users. Psychopharmacology 207(4):583–591. https://doi.org/10.1007/s00213-009-1688-z
Screaton GR, Cairns HS, Samer M et al (1992) Hyperpyrexia and rhabdomyolysis after MDMA ('ecstasy’) abuse. Lancet 339(8794):677–678. https://doi.org/10.1016/0140-6736(92)90834-p
Sessa B (2015) The ecstatic history of MDMA: from raving highs to saving lives. Breaking Convention Book of Proceedings from the 2013 Conference. Strange Attractor Press, London, pp 87–94
Sessa B, Higbed L, Nutt D (2019) A review of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy. Front Psychopharmacology 10:138. https://doi.org/10.3389/fpsyt.2019.00138
Sessa B, Higbed L, O’Brien S, Durant C, Sakal C, Titheradge D et al (2021) First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder. J Psychopharmacol 35:375–383. https://doi.org/10.1177/0269881121991792
Shulgin AT (1986) The background and chemistry of MDMA. J Psychoactive Drugs 18(4):291–304. https://doi.org/10.1080/02791072.1986.10472361
Simmler L, Buser T, Donzelli M, Schramm Y, Dieu LH, Huwyler J et al (2013) Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 168:458–470. https://doi.org/10.1111/j.1476-5381.2012.02145.x
Simmler LD, Rickli A, Hoener MC, Liechti ME (2014a) Monoamine transporter and receptor interaction profiles of a new series of designer cathinones. Neuropharmacology 79:152–160. https://doi.org/10.1016/j.neuropharm.2013.11.008
Simmler LD, Rickli A, Schramm Y, Hoener MC, Liechti ME (2014b) Pharmacological profiles of aminoindanes, piperazines, and pipradrol derivatives. Biochem Pharmacol 88:237–244. https://doi.org/10.1016/j.bcp.2014.01.024
Solowij N, Hall W, Lee N (1992) Recreational MDMA use in Sydney: a profile of “Ecstacy” users and their experiences with the drug. Br J Addict 87(8):1161–1172. https://doi.org/10.1111/j.1360-0443.1992.tb02003.x
Steenkamp MM, Litz B, Hoge CW, Marmar CR (2015) Psychotherapy for military-related PTSD: a review of randomized clinical trials. JAMA 314:489–500. https://doi.org/10.1001/jama.2015.8370
Suarez RV, Riemersma R (1988) “Ecstasy” and sudden cardiac death. Am J Forensic Med Pathol 9:339–341. https://doi.org/10.1097/00000433-198812000-00015
TGA classification of psilocybin and MDMA (2023) Available at: https://www.tga.gov.au/news/media-releases/change-classification-psilocybin-and-mdma-enable-prescribing-authorised-psychiatrists (Accessed Sept 20 2023).
Thompson MR, Callaghan PD, Hunt GE, Cornish JL, McGregor IS (2007) A role for oxytocin and 5-HT(1A) receptors in the prosocial effects of 3,4 methylenedioxymethamphetamine (“ecstasy”). Neuroscience 146(2):509–514. https://doi.org/10.1016/j.neuroscience.2007.02.032
Tolerability of MDMA in Schizophrenia (TMS) (2023) Available at: https://clinicaltrials.gov/study/NCT05770375. (Accessed Oct 3, 2023)
Topp L, Hall W, Hando J (1997) Is there a dependence syndrome for ecstasy? NDARC Technical Report No. 51. Available at: https://ndarc.med.unsw.edu.au/sites/default/files/ndarc/resources/TR.051.pdf. (Accessed April 4, 2024)
UNODC early warning advisory on new psychoactive substances (2023) https://www.unodc.org/LSS/Page/NPS; UNDOC Current NPS threats Vol VI August 2023 https://www.unodc.org/res/scientists/ewa/Current_NPS_Threats_VI.pdf) (Accessed Sept 3, 2023).
van Wel JH, Kuypers KP, Theunissen EL, Bosker WM, Bakker K, Ramaekers JG (2012) Effects of acute MDMA intoxication on mood and impulsivity: role of the 5-HT2 and 5-HT1 receptors. PLoS ONE 7(7):e40187. https://doi.org/10.1371/journal.pone.0040187
Verrico CD, Miller GM, Madras BK (2007) MDMA (Ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology 189(4):489–503. https://doi.org/10.1007/s00213-005-0174-5
Vizeli P, Liechti ME (2017) Safety pharmacology of acute MDMA administration in healthy subjects. J Psychopharmacol 31:576–588. https://doi.org/10.1177/0269881117691569
Vizeli P, Schmid Y, Prestin K, Schwabedissen MZ, HE, Liechti ME, (2017) Pharmacogenetics of ecstasy: CYP1A2, CYP2C19, and CYP2B6 polymorphisms moderate pharmacokinetics of MDMA in healthy subjects. Eur Neuropsychopharmacol 27(3):232–238. https://doi.org/10.1016/j.euroneuro.2017.01.008
Vollenweider FX, Gamma A, Liechti M, Huber T (1998) Psychological and cardiovascular effects and short-term sequelae of MDMA (“ecstasy”) in MDMA-naïve healthy volunteers. Neuropsychopharmacology 19(4):241–251. https://doi.org/10.1016/S0893-133X(98)00013-X
Walsh T, Carmichael R, Chestnut R (1994) A hyperthermic reaction to “ecstasy.” Br J Hosp Med 51:476
Weathers FW, Keane TM, Davidson JR (2001) Clinician-administered PTSD scale: a review of the first ten years of research. Depress Anxiety 13:132–156. https://doi.org/10.1002/da.1029
Williams P (2005) Correlates of ecstasy use in middle age and beyond. Drug Alcohol Rev 24(1):33–38. https://doi.org/10.1080/09595230500124925
Wolff K, Tsapakis EM, Winstock AR, Hartley D, Holt D, Forsling ML, Aitchison K (2006) Vasopressin and oxytocin secretion in response to the consumption of ecstasy in a clubbing population. J Psychopharmacol 20(3):400–410. https://doi.org/10.1177/0269881106061514
Wolfson PE, Andries J, Feduccia AA, Jerome L, Wang JB, Williams E et al (2020) MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study. Sci Rep 10(1):20442. https://doi.org/10.1038/s41598-020-75706-1
Funding
No funding was received to assist in the preparation of this review.
Author information
Authors and Affiliations
Contributions
The author undertook the literature review, wrote and reviewed the draft, prepared the final manuscript, and agrees to be accountable for all aspects of the work.
Corresponding author
Ethics declarations
Conflict of interest
The author declares no known competing financial interests or personal relationships that influenced the work reported here.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The author is retired. The positions and affiliations are those prior to his retirement:.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Baldo, B.A. The entactogen 3,4-methylenedioxymethamphetamine (MDMA; ecstasy) as a treatment aid in psychotherapy and its safety concerns. Arch Toxicol (2024). https://doi.org/10.1007/s00204-024-03765-8
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s00204-024-03765-8